FIALURIDINE
Non Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
67 Active assets in the Non Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Chimeric Antigen Receptor Modified T Cells Infusion University of Texas Southwestern Medical Center | Phase 2 | BB |
Eloxatin Hoffmann-La Roche | Phase 3 | BB |
Acalabrutinib Narendranath Epperla | Phase 2 | BB |
Tafasitamab Paolo Caimi, MD | Phase 2 | B |
PRILOCAINE Federal University of Minas Gerais | Phase 4 | B |
View all 50 →
Same molecule, other indications
FIALURIDINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →